Los Angeles Capital Management LLC Buys Shares of 121,225 Zevra Therapeutics, Inc. $ZVRA

Los Angeles Capital Management LLC purchased a new stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 121,225 shares of the company’s stock, valued at approximately $1,068,000. Los Angeles Capital Management LLC owned 0.22% of Zevra Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Bank of New York Mellon Corp increased its holdings in shares of Zevra Therapeutics by 11.0% in the 1st quarter. Bank of New York Mellon Corp now owns 120,433 shares of the company’s stock worth $902,000 after acquiring an additional 11,946 shares during the period. Mystic Asset Management Inc. grew its position in Zevra Therapeutics by 8.2% in the 1st quarter. Mystic Asset Management Inc. now owns 338,902 shares of the company’s stock worth $2,538,000 after purchasing an additional 25,555 shares during the last quarter. AIGH Capital Management LLC grew its position in Zevra Therapeutics by 82.4% in the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company’s stock worth $10,771,000 after purchasing an additional 649,495 shares during the last quarter. Readystate Asset Management LP increased its stake in shares of Zevra Therapeutics by 924.6% in the first quarter. Readystate Asset Management LP now owns 683,032 shares of the company’s stock valued at $5,116,000 after purchasing an additional 616,370 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Zevra Therapeutics by 2.6% during the first quarter. Charles Schwab Investment Management Inc. now owns 153,331 shares of the company’s stock valued at $1,148,000 after buying an additional 3,827 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Wall Street Zen raised Zevra Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Cantor Fitzgerald cut their target price on Zevra Therapeutics from $29.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, November 6th. Zacks Research cut Zevra Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 18th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday, August 13th. Finally, Canaccord Genuity Group reduced their price objective on shares of Zevra Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Thursday, November 6th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Zevra Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $22.80.

Insider Transactions at Zevra Therapeutics

In other Zevra Therapeutics news, Director John B. Bode bought 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 19th. The shares were acquired at an average cost of $9.16 per share, for a total transaction of $45,800.00. Following the acquisition, the director directly owned 45,000 shares of the company’s stock, valued at $412,200. This trade represents a 12.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Neil F. Mcfarlane sold 19,500 shares of the stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $10.82, for a total transaction of $210,990.00. Following the sale, the chief executive officer directly owned 222,016 shares of the company’s stock, valued at approximately $2,402,213.12. This represents a 8.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 2.40% of the stock is currently owned by corporate insiders.

Zevra Therapeutics Stock Down 0.3%

Shares of ZVRA stock opened at $9.40 on Thursday. Zevra Therapeutics, Inc. has a 1 year low of $6.19 and a 1 year high of $13.16. The company has a debt-to-equity ratio of 0.52, a quick ratio of 7.81 and a current ratio of 7.85. The business’s fifty day moving average is $9.57 and its 200-day moving average is $9.61. The stock has a market cap of $529.20 million, a PE ratio of -44.76 and a beta of 1.52.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.03. The business had revenue of $26.06 million during the quarter, compared to analyst estimates of $26.64 million. Zevra Therapeutics had a negative return on equity of 112.40% and a net margin of 4.33%. Equities analysts expect that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.